Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th

FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced its intention to voluntarily delist its common stock from The New York Stock Exchange ("NYSE") and to have its common stock quoted on the OTCQX Best Market ("OTCQX"). Enzo provided notice of the voluntary delisting to the NYSE on March 28, 2025 and intends to timely file a notification of removal from listing on Form 25 with the Securities and Exchange Commission (the "SEC") to effect the delisting.  It is anticipated that the delisting will become effective on or about April 17, 2025, with trading on OTCQX to commence on or about April 18, 2025. This announceme

FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross margin and operating profit / loss. Financial Highlights The Company's second-quarter gross margin percentage of 52% increased sequentially from 37% during Q1 2025 and increased from 49% during the second quarter of the prior year. These improvements were driven by change in revenues, cost efficiency actions completed, and mix of products sold.The Enzo Life Sciences Products segment, which excludes discontinued operations and Corporate over

FARMINGDALE, N.Y, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced that it was notified by the New York Stock Exchange (the "NYSE") that it is not in compliance with Section 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) its 30 trading-day average market capitalization was less than $50 million and its last reported stockholder's equity as of October 31, 2024 was less than $50 million and (ii) the average closing price of the Company's Common Stock (the "Common Stock") was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and st

4 - ENZO BIOCHEM INC (0000316253) (Issuer)

4 - ENZO BIOCHEM INC (0000316253) (Issuer)

4 - ENZO BIOCHEM INC (0000316253) (Issuer)

8-K - ENZO BIOCHEM INC (0000316253) (Filer)

8-K - ENZO BIOCHEM INC (0000316253) (Filer)

10-Q - ENZO BIOCHEM INC (0000316253) (Filer)

FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D. to the Company's Board of Directors to hold office for a term ending as of our Fiscal 2024 annual meeting of shareholders, and until each such director's successor is elected and qualified. Proposal Two – The shareholders did not approve, by a non

FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) --  Enzo Biochem, Inc. (NYSE:ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo's Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. "We thank Hamid for the commitment he has brought to Enzo Biochem, Inc."  Chairperson of the Board Mary Tagliaferri, MD stated, "Hamid successfully led the Company through the divestiture of Enzo Clinical Lab, Inc.  We wish him well in all his future endeavors and are excited to focus on the life sciences division. We are confident in Kara to lead th

NEW YORK, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO).  Ms. Eckert's appointment follows the resignation of David Bench, who is departing the Company effective November 14, 2022 to pursue a new opportunity. "While bittersweet in light of David's departure, we are exceedingly pleased to have Patricia in position to advance into the position of interim CFO," remarked Hamid Erfanian, CEO of Enzo. "Patricia is exceptionally qualified given her years of experience and comprehensive knowledge of Enzo'

FARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal first quarter ended October 31, 2024. First Quarter Highlights Enzo ended the first quarter with aggregate cash and cash equivalents of $47.7 million. The net cash used in operating activities during the first quarter decreased by $4.4 million compared to the prior year. The Company's first-quarter revenue of $6.2 million declined year-over-year by 20% due to declining market demand related to general continued headwinds in the life sciences tools space. Recent Events The declared special cash dividend of $0.10 per share on its

FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company's revenues in the 2024 period of $31.9 million improved year-over-year by 3%. Enzo's sales to its industrial customers, which includes biotech and pharmaceutical companies, increased 46% driven by our drug development and cell and gene therapy focus.The Company's FY24 gross margin was 46%. The prio

Highlights the Destruction of 70% in Stockholder Value Under Garry Mauro's 10-Year Reign as Chairman Notes the Radoff-Sudbury Group's Aligned and Highly Qualified Director Candidates Collectively Own Significantly More Stock than the Entire LifeVantage Board and are Committed to Acting in Stockholders' Best Interests Urges Stockholders to Vote for the Radoff-Sudbury Group's Director Candidates – Dayton Judd, Michael Lohner and Bradley L. Radoff – on the BLUE Proxy Card Ahead of LifeVantage's Upcoming Annual Meeting Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the "Radoff-Sudbury Group" or "we"), who collectively own approximately 12.8% of the outstan

SC 13G/A - ENZO BIOCHEM INC (0000316253) (Subject)

SC 13G/A - ENZO BIOCHEM INC (0000316253) (Subject)

SC 13G - ENZO BIOCHEM INC (0000316253) (Subject)